[{"company":"EyePoint Pharmaceuticals","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","amount":"$21.7 million","upfrontCash":"Undisclosed","newsHeadline":"EyePoint Pharmaceuticals Announces Proposed Public Offering","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"EyePoint Pharmaceuticals"},{"company":"EyePoint Pharmaceuticals","sponsor":"Ocumension Therapeutics","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"$2.0 million","newsHeadline":"Ocumension inks $14M deal with EyePoint Pharma","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"EyePoint Pharmaceuticals"},{"company":"Abigo Medical AB","sponsor":"Essity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Essity Acquires 75% of the Medical Solutions Company ABIGO Medical AB","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Abigo Medical AB"},{"company":"Genfa Medica","sponsor":"MediWound","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Strengthens its NexoBrid European Presence with Additional Distribution Agreements with Genfa Medica","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Genfa Medica"},{"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Receives Marketing Authorization for Lyfaquin\u2122 (centhaquine) from Indian Regulatory Agency","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Pharmazz"},{"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Submission of Biologics License Application to the U.S. FDA for NexoBrid for the Treatment of Severe Thermal Burns","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Large molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"MediWound"},{"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lyfaquin\u00ae, a First-in-class Resuscitative Agent for Patients with Excessive Blood Loss, to be Launched in India","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Pharmazz"},{"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Large molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"MediWound"},{"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Completes Enrollment Stage of its NexoBrid Phase 3 Pediatric Study","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Large molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"MediWound"},{"company":"MediWound","sponsor":"Ghassan Aboud Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Continues Global Expansion with Distribution Agreement for in United Arab Emirates with Ghassan Aboud Group","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Large molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"MediWound"},{"company":"BioStem Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioStem Technologies, Inc. Receives TRIP (TRG Rapid Inquiry Program) Response for VENDAJE\u2122","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"BioStem Technologies"},{"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resuscitative Effect of Centhaquine (Lyfaquin\u00ae) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Pharmazz"},{"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mallinckrodt Gets FDA Nod for Strata Graft Thermal Burn Treatment","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Cell and Gene therapy","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Mallinckrodt Pharmaceuticals"},{"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Large molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"MediWound"},{"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approved IND Submitted by Pharmazz, Inc. to Initiate a Phase III Clinical Trial of Centhaquine in Patients with Hypovolemic Shock","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Pharmazz"},{"company":"Omeros","sponsor":"Rayner Surgical Group Limited","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$125.0 million","newsHeadline":"Omeros Announces Agreement to Sell OMIDRIA\u00ae Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Omeros"},{"company":"Avita Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL\u00ae System for Soft-Tissue Reconstruction","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Avita Medical"},{"company":"MediWound","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","amount":"$211.0 million","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA Resubmission and the Expanded Access Treatment Protocol","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Large molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"MediWound"},{"company":"Vericel Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America (BRCA) of Patients with Large Posterior Trunk Burns Treated with Epicel","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Vericel Corporation"},{"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Large molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"MediWound"},{"company":"Megalabs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Megalabs USA Announces Launch of Two New Products in North American Market: Abintra and Glutapak R","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"BRAZIL","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Megalabs"},{"company":"BioStem Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioStem Announces Publication of a Standardized Method to Evaluate Growth Factor Elution from Placental Tissue Allografts","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"BioStem Technologies"},{"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pharmazz Inc. Presents Data From its Positive Phase III Study of Centhaquine (PMZ-2010) as a Resuscitative Agent in Hypovolemic Shock Patients at Upcoming Military Health System Research Symposium","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Pharmazz"},{"company":"MiMedx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MIMEDX Announces Launch of AXIOFILL\u2122","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"MiMedx"}]
Details:
AXIOFILL is an acellular human extracellular matrix (ECM) derived from the placental disc. AXIOFILL preserves multiple ECM components and other matrix-bound proteins and is intended for use in the replacement or supplementation of damaged or inadequate integumental tissue.
Lead Product(s):
Acellular Human Extracellular Matrix
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: Axiofill
Highest Development Status: Approved
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 20, 2022
Details:
The study investigates a standardized method to quantify the elution of growth factors and cytokines in BioStem’s dehydrated amniotic membrane (Vendaje®) and dehydrated amnion/chorion (Vendaje AC®) placental derived allografts as a function of surface (cm2).
Lead Product(s):
Dehydrated Human Amniotic Membrane
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: Vendaje
Highest Development Status: Approved
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 13, 2022
Details:
The positive results seen in the Phase III study indicate that Lyfaquin (centhaquine) is a highly safe and efficacious resuscitative agent as an adjuvant to the standard of care and would be a addition to the U.S. Military’s medical resources that can save numerous lives.
Lead Product(s):
Centhaquine
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: Lyfaquin
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 13, 2022
Details:
Abintra features a unique combination of arginine, glutamine, high-quality protein, and antioxidant vitamins and minerals in a quick-dissolving powder. The formula works to promote tissue synthesis and wound healing from within.
Lead Product(s):
Abintra
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: Abintra
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 24, 2022
Details:
NexoBrid (bromelain) is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns within four hours of application without harming viable tissue.
Lead Product(s):
Bromelain
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: NexoBrid
Highest Development Status: Approved
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 03, 2022
Details:
Data published in the Journal of Burn Care & Research for Epicel® (cultured epidermal autografts) showed 83% of patients with posterior burns (mean total body surface area of 56%) had successful engraftment of Epicel after one or two applications.
Lead Product(s):
Cultured Epidermal Autograft
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: Epicel
Highest Development Status: Approved
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 21, 2022
Details:
BARDA is providing funds to develop NexoBrid & support NexoBrid’s potential approval to enhance U.S preparedness. NexoBrid, product for non-surgical eschar removal & full-thickness thermal burns, is a bromelain-based product containing a sterile mixture of proteolytic enzymes.
Lead Product(s):
Bromelain
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: NexoBrid
Highest Development Status: Approved
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Biomedical Advanced Research and Development Authority
Deal Size: $211.0 million
Upfront Cash: Undisclosed
Deal Type: Funding
February 10, 2022
Details:
Enrollment of Pivotal trial for Recell (Regenerative Epidermal Suspension) is completed and topline result are expecting in the second half of 2022 for treatment of soft-tissue reconstruction.
Lead Product(s):
Regenerative Epidermal Suspension
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: Recell
Highest Development Status: Approved
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 06, 2022
Details:
As part of the agreement, Rayner will acquire the OMIDRIA commercial organization, including the OMIDRIA sales force. Rayner plans to expand the sales force in both the U.S. and ex-U.S., and further accelerating U.S. market growth of OMIDRIA.
Lead Product(s):
Phenylephrine Hydrochloride,Ketorolac Trometamol
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: Omidria
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Rayner Surgical Group Limited
Deal Size: $1,000.0 million
Upfront Cash: $125.0 million
Deal Type: Agreement
December 02, 2021
Details:
Centhaquine converts the venous unstressed blood volume to stressed blood volume and improves cardiac output and blood circulation. Centhaquine (Lyfaquin®) as a Resuscitative Agent in Hypovolemic Shock Patients.
Lead Product(s):
Centhaquine
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: Lyfaquin
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 29, 2021
Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
